Schumacher H, Von Tengg-Kobligk H, Ostovic M, Henninger V, Ockert S, Böckler D, Allenberg J R
Clinic for Vascular and Endovascular Surgery, Academic Teaching Hospital Hanau, Hanau, Germany.
J Cardiovasc Surg (Torino). 2006 Oct;47(5):509-17.
The aim of this study was to report our clinical experience with and review current literature on endoluminal aortic hybrid techniques and to evaluate outcome in high-risk patients treated for complex aortic arch lesions combining conventional supra-aortic debranching bypasses with subsequent or staged thoracic endovascular grafting. Of 172 patients treated with thoracic endografts for different thoracic aortic pathologies within the last 8 years, the mid-aortic arch was involved in 25, i.e. at least the left common carotid artery had to be overstented and revascularized to provide a proper proximal landing zone. These debranching bypasses were performed as a simultaneous or a staged procedure. All patients were at high-risk and were excluded by cardiac surgeons as ineligible for conventional arch repair. After partial (n=16) or complete (n=9) supra-aortic transposition, 4 different commercially available endografts (80% TAG, WL Gore) were implanted transfemorally or via iliac conduit. Deployment success was 100% in 25 patients after simultaneous or staged supra-aortic transposition; in 32% an emergency procedure was performed due to contained rupture; in 36% more than 1 endograft system was implanted (2 in 20%, 3 in 8% und 4 in 8%). The overall perioperative thirty-day mortality was 5 of 25 (20%) due to interoperative proximal bare stent perforation (n=1), transfusion related acute lung injury (TRALI n=1), cardiac failure (n=1), embolic stroke (n=1) and pneumonia (n=1). The mean follow-up was 21 months. All endoleaks type I (n=3) were corrected with another endograft; the 2 endoleaks type II sealed spontaneously. The major adverse events were: prolonged ventilation in 5 (20%), temporary renal insufficiency with hemodialysis (n=2), bypass infection (n=1), without any complications (n=9). No cases of paraplegia were recorded. Hybrid aortic arch repair is technically challenging but feasible. This novel approach may be an alternative to standard open procedures in high-risk patients and emergency cases. However, the promising early results need to be confirmed by longer follow-up and larger series.
本研究的目的是报告我们在腔内主动脉杂交技术方面的临床经验并回顾当前文献,评估采用传统主动脉弓上分支旁路联合后续或分期胸段血管腔内移植物植入术治疗复杂主动脉弓病变的高危患者的治疗结果。在过去8年中,172例因不同胸主动脉病变接受胸段血管腔内移植物治疗的患者中,25例累及主动脉弓中部,即至少左颈总动脉必须进行支架植入和血运重建以提供合适的近端锚定区。这些分支旁路手术采用同期或分期手术。所有患者均为高危患者,心脏外科医生认为他们不适合进行传统的主动脉弓修复手术。在部分(n = 16)或完全(n = 9)主动脉弓上转位后,经股动脉或通过髂血管导管植入4种不同的市售血管腔内移植物(80%为TAG,WL Gore公司)。在同期或分期主动脉弓上转位后,25例患者的植入成功率为100%;32%的患者因局限性破裂而进行了急诊手术;36%的患者植入了不止1个血管腔内移植物系统(20%植入2个,8%植入3个,8%植入4个)。围手术期30天总死亡率为25例中的5例(20%),原因包括术中近端裸支架穿孔(n = 1)、输血相关急性肺损伤(TRALI,n = 1)、心力衰竭(n = 1)、栓塞性卒中(n = 1)和肺炎(n = 1)。平均随访时间为21个月。所有I型内漏(n = 3)均通过植入另一个血管腔内移植物进行了纠正;2例II型内漏自行闭合。主要不良事件包括:5例(20%)通气时间延长、2例需要血液透析的暂时性肾功能不全、1例旁路感染、9例无任何并发症。未记录到截瘫病例。杂交主动脉弓修复技术上具有挑战性,但可行。这种新方法可能是高危患者和急诊病例中标准开放手术的替代方法。然而,这些有前景的早期结果需要通过更长时间的随访和更大规模的系列研究来证实。